Search
Lung Cancer Paid Clinical Trials in Pennsylvania
A listing of 119 Lung Cancer clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
49 - 60 of 119
The state of Pennsylvania currently has 119 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Offer
On Medicare? GLP-1's Covered By Medicare Part D [Found Partnership]
Found is now serving individuals who are 65-75 with GLP-1 support for weight care. You need Medicare Part D, must be 18 or older, and must meet BMI criteria when you start GLP-1 therapy:
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
Conditions:
Healthy
Overweight
Overweight and Obesity
Obesity
Overweight or Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Therapy
Bladder leaks? This system might be the answer
Struggling with bladder leaks? Get bladder control beyond pills. The InterStimᵀᴹ system is an FDA-approved treatment that may help you regain control.
Take our quick survey to see if this system could work for you.
Risks may include surgical, device, and stimulation-related complications. See important safety info: https://83b.co/tlcbld
Take our quick survey to see if this system could work for you.
Risks may include surgical, device, and stimulation-related complications. See important safety info: https://83b.co/tlcbld
Conditions:
Overactive Bladder
Urinary Incontinence
Idiopathic Overactive Bladder
Incontinence
Healthy
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/04/2025
Locations: Clinical Research Associates of Central PA, DuBois, Pennsylvania +4 locations
Conditions: Lung Cancer Diagnosis
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/04/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency, Untreated Advanced NSCLC, 1st Line NSCLC
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Recruiting
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Recruiting
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Abramson Cancer Center, Philadelphia, Pennsylvania +1 locations
Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Empathic Communication Skills (ECS) Training
Recruiting
Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appears to be a potentially effective intervention target to help reduce patients' perceptions of stigma within clinical encounters; however, no formal trainings exist that focus on teaching empathic communication to oncology care providers (OCPs). Building upon favorable findings from a prior R21 (R21CA2... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/31/2025
Locations: Virtua Health (Data Collection Only), Philadelphia, Pennsylvania +1 locations
Conditions: Lung Cancer
Community Support Program for Lung Cancer Screening Volume II
Recruiting
This is a West Philadelphia based community project to improve adherence to lung cancer screening. The overall objective of this project is to demonstrate the impact of a community support program (CSP) on improve adherence to LCS follow-up guidelines in an urban environment. The study will target individuals in the Penn Medicine healthcare system residing in Philadelphia with an upcoming or missed follow-up screening or orders placed but who have not yet scheduled their screenings by offering f... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/30/2025
Locations: Univeristy of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancer
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Recruiting
Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits
Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
Recruiting
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess self-reported preferences and needs of patients with SCLC, regarding choosing and accessing novel therapies in research or standard clinical care settings and supportive gaps in this area, through an initial and 3 month follow up survey.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html, Multiple Locations, Pennsylvania
Conditions: Small-cell Lung Cancer
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
Recruiting
The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete.
The second phase is a single arm phase 1 safety study. Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Early Stage Non-Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Recruiting
This Phase 2b, multicohort, open-label clinical trial (QUILT-3.055) evaluates combination immunotherapies in patients with various advanced solid tumors who have progressed following prior PD-1/PD-L1 checkpoint inhibitor therapy. The trial includes six cohorts:
Cohorts 1-4: Patients who progressed after an initial response (PR or CR) to prior PD-1/PD-L1 therapy, receiving combination therapy with N-803 and a PD-1/PD-L1 checkpoint inhibitor. (Closed to enrollment)
Cohort 5: Patients who progres... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Gettysburg/Hanover Cancer Centers, Gettysburg, Pennsylvania
Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Recruiting
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer.
Livmoniplimab is an investigational drug being developed for the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Guthrie Robert Packer Hospital /ID# 262758, Sayre, Pennsylvania
Conditions: Non-Small Cell Lung Cancer
49 - 60 of 119
